ATE498406T1 - Dna-vakzine für die krebstherapie - Google Patents

Dna-vakzine für die krebstherapie

Info

Publication number: ATE498406T1
Authority: AT; Austria
Prior art keywords: fusion gene; dna encoding; gene; cancer; cancer therapy
Prior art date: 2005-12-19

Application number

AT06832315T

Other languages

English (en)

Inventor

Kapil Maithal

Paromita Sengupta

Rama Mukherjee

Original Assignee

Fresenius Kabi Oncology Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-12-19

Filing date

2006-12-19

Publication date

2011-03-15

2006-12-19 Application filed by Fresenius Kabi Oncology Ltd filed Critical Fresenius Kabi Oncology Ltd

2011-03-15 Application granted granted Critical

2011-03-15 Publication of ATE498406T1 publication Critical patent/ATE498406T1/de

Links

229960005486 vaccine Drugs 0.000 title abstract 2
238000011275 oncology therapy Methods 0.000 title 1
206010028980 Neoplasm Diseases 0.000 abstract 3
230000004927 fusion Effects 0.000 abstract 3
108090000623 proteins and genes Proteins 0.000 abstract 3
108090000848 Ubiquitin Proteins 0.000 abstract 2
201000011510 cancer Diseases 0.000 abstract 2
102000009465 Growth Factor Receptors Human genes 0.000 abstract 1
108010009202 Growth Factor Receptors Proteins 0.000 abstract 1
102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 abstract 1
108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 abstract 1
102000055135 Vasoactive Intestinal Peptide Human genes 0.000 abstract 1
108010003205 Vasoactive Intestinal Peptide Proteins 0.000 abstract 1
102100038388 Vasoactive intestinal polypeptide receptor 1 Human genes 0.000 abstract 1
101710137655 Vasoactive intestinal polypeptide receptor 1 Proteins 0.000 abstract 1
239000000427 antigen Substances 0.000 abstract 1
230000030741 antigen processing and presentation Effects 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
230000001413 cellular effect Effects 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
230000003053 immunization Effects 0.000 abstract 1
238000002649 immunization Methods 0.000 abstract 1
VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 abstract 1
UFTCZKMBJOPXDM-XXFCQBPRSA-N pituitary adenylate cyclase-activating polypeptide Chemical compound C([C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 UFTCZKMBJOPXDM-XXFCQBPRSA-N 0.000 abstract 1
229940021993 prophylactic vaccine Drugs 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
229940021747 therapeutic vaccine Drugs 0.000 abstract 1
230000004614 tumor growth Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Toxicology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Microbiology (AREA)
Wood Science & Technology (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Biomedical Technology (AREA)
Vascular Medicine (AREA)
Epidemiology (AREA)
Mycology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Endocrinology (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT06832315T 2005-12-19 2006-12-19 Dna-vakzine für die krebstherapie ATE498406T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IN3393DE2005		2005-12-19
PCT/IN2006/000497 WO2007072504A1 (en)	2005-12-19	2006-12-19	Dna vaccine for cancer therapy

Publications (1)

Publication Number	Publication Date
ATE498406T1 true ATE498406T1 (de)	2011-03-15

Family

ID=37889816

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06832315T ATE498406T1 (de)	2005-12-19	2006-12-19	Dna-vakzine für die krebstherapie

Country Status (7)

Country	Link
US (1)	US20090221682A1 (de)
EP (1)	EP1962891B1 (de)
AT (1)	ATE498406T1 (de)
AU (1)	AU2006327514B2 (de)
CA (1)	CA2633346A1 (de)
DE (1)	DE602006020172D1 (de)
WO (1)	WO2007072504A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2009094561A1 (en) *	2008-01-24	2009-07-30	The Government Of The United States Of America As Represented By The Secretary Of The Departmentof	Induced internalization of surface receptors
CN103933557B (zh) *	2014-04-29	2015-11-18	中国人民解放军南京军区福州总医院四七六医院	一种神经胶质瘤的双向调节治疗性疫苗及其制备方法
SG10202011027QA (en) *	2016-05-05	2020-12-30	Univ Pennsylvania	Dna monoclonal antibodies targeting checkpoint molecules
WO2018156106A1 (en) *	2017-02-22	2018-08-30	Ding Enyu	An mrna cancer vaccine encoding human gm-csf fused to multiple tandem epitopes
CA3092860A1 (en) *	2018-03-06	2019-09-12	Pepvax, Inc.	Nucleic acid molecules and methods of using the same
US12319720B2 (en) *	2021-08-31	2025-06-03	Washington University	Neoantigen vaccines for triple negative breast cancer

2006
- 2006-12-19 AT AT06832315T patent/ATE498406T1/de not_active IP Right Cessation
- 2006-12-19 DE DE602006020172T patent/DE602006020172D1/de active Active
- 2006-12-19 US US12/086,710 patent/US20090221682A1/en not_active Abandoned
- 2006-12-19 CA CA002633346A patent/CA2633346A1/en not_active Abandoned
- 2006-12-19 AU AU2006327514A patent/AU2006327514B2/en not_active Ceased
- 2006-12-19 EP EP06832315A patent/EP1962891B1/de active Active
- 2006-12-19 WO PCT/IN2006/000497 patent/WO2007072504A1/en not_active Ceased

Also Published As

Publication number	Publication date
CA2633346A1 (en)	2007-06-28
WO2007072504A1 (en)	2007-06-28
EP1962891B1 (de)	2011-02-16
AU2006327514A1 (en)	2007-06-28
DE602006020172D1 (de)	2011-03-31
EP1962891A1 (de)	2008-09-03
US20090221682A1 (en)	2009-09-03
AU2006327514B2 (en)	2010-04-15

Legal Events

Date	Code	Title	Description
2011-08-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
WO2007130455A3 (en)	2008-11-20	Compositions and methods for treatment of non-hodgkins lymphoma
ATE482972T1 (de)	2010-10-15	Tgf-beta1-bindende und geträgerte peptide
MX2020010806A (es)	2020-10-28	Peptidos anti-inflamatorios y usos de los mismos.
GEP20105111B (en)	2010-11-10	Rage fusion proteins and methods of use
JP2015516813A5 (de)	2017-10-12
WO2007106476A3 (en)	2008-08-21	Compositions and methods for enhancing the immunogenicity of antigens
CL2008003323A1 (es)	2009-03-06	Uso de un anticuerpo que se une a cd20 porque sirve para preparar un medicamento para tratar enfermedades autoinmunes; acido nucleico que codifica una proteina cd20 de mono cynomolgus; vector que lo comprende; celula huesped y polipeptido cd20 de mono cynomolgus (div.sol.no.2639-03).
PE20091713A1 (es)	2009-11-13	Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos
EA200700136A1 (ru)	2007-08-31	Анти-cd154-антитела
PE20211300A1 (es)	2021-07-20	Peptidos y combinacion de peptidos de origen no canonico para el uso en la inmunoterapia contra diferentes tipos de cancer
TW201129379A (en)	2011-09-01	Anti-Orai1 antigen binding proteins and uses thereof
AR076977A1 (es)	2011-07-20	Proteinas precursoras repetitivas autoensambladas
MX363326B (es)	2019-03-20	Metodo para incrementar el volumen hidrodinamico de polipeptidos mediante la union a peptidos carboxi-terminales de gonadotrofina.
JP2015532644A5 (de)	2016-06-02
BRPI0606612A2 (pt)	2009-07-07	expressão recombinante de proteìnas em uma forma de duas cadeias ligadas por dissulfeto
JP2015525208A5 (de)	2016-06-02
WO2007064917A3 (en)	2008-03-13	Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
AR105616A1 (es)	2017-10-25	Proteínas de fusión
JP2015535816A5 (de)	2016-11-04
UA110599C2 (uk)	2016-01-25	Пептид для імунотерапії пухлин, включаючи нейрональні пухлини та пухлини мозку
EA201291362A1 (ru)	2013-06-28	Слитый белок против злокачественных новообразований
NZ713461A (en)	2017-02-24	Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
CN114835795A (zh)	2022-08-02	用于延长蛋白质半衰期的方法
PE20070684A1 (es)	2007-08-06	MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
TW200510450A (en)	2005-03-16	Soluble fragments of the SARS-CoV spike glycoprotein